• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    BioNTech SE - American Depositary Shares (NQ:BNTX)

    107.20 +3.29 (+3.17%)
    Streaming Delayed Price Updated: 9:30 AM EST, Nov 3, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about BioNTech SE - American Depositary Shares

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    70 71 Next >
    Bristol Myers To Pay Up To $11.1B To BioNTech To Co-Develop, Commercialize Investigational Cancer Drug
    BMS will pay BioNTech $1.5 billion in an upfront payment in the second quarter and $2 billion in non-contingent anniversary payments through 2028. 
    Via Stocktwits
    Topics Government
    Why Blueprint Medicines Shares Are Trading Higher By 27%; Here Are 20 Stocks Moving Premarket
     
    Via Benzinga
    BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types
    From Bristol Myers Squibb
    Via Business Wire
    Earnings Scheduled For May 5, 2025
     
    Via Benzinga
    BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types
    From BioNTech SE
    Via GlobeNewswire
    Robert F. Kennedy Jr. Says CDC Drops COVID Vaccine For 'Healthy' Pregnant Women, Children
    RFK Jr. says the COVID-19 vaccine is no longer on the CDC's recommended schedule for healthy kids and pregnant women, though the official site still shows it listed. 
    Via Benzinga
    BioNTech to Present Progress Across Diversified Oncology Pipeline at the 2025 ASCO Annual Meeting
    From BioNTech SE
    Via GlobeNewswire
    FDA Limits Annual COVID-19 Boosters To High-Risk Americans, Demands New Trials For Healthy Adults In Policy Shift Under RFK Jr.
    The U.S. Food and Drug Administration has announced significant changes to COVID-19 vaccine requirements, limiting annual booster approvals to older and high-risk Americans while implementing stricter... 
    Via Benzinga
    What's Going On With Vaccine Stocks Today?
    Shares of Vaccine stocks are moving higher on Tuesday after documents from the U.S. Food and Drug Administration revealed that its advisers will meet this week. 
    Via Benzinga
    The FDA Is Limiting Covid Shots. But Moderna, Vaccine Stocks Jumped.
    The new framework limits future Covid shots to people age 65 and older and those six months and older with a risk factor for serious illness. 
    Via Investor's Business Daily
    Topics Bankruptcy Government
    Novavax Scores Key FDA Win, Shares Jump 19% As Sanofi Unlocks Milestone Payment
    Novavax's COVID-19 vaccine, Nuvaxovid™, receives limited FDA approval and triggers $175M milestone payment. Commercial distribution planned for fall. 
    Via Benzinga
    Novavax Wins Limited FDA Nod For COVID Shot—Cleared Only For Seniors, High-Risk Groups Amid Safety Scrutiny
    The U.S. Food and Drug Administration has granted limited approval to Novavax Inc.'s COVID-19 vaccine, restricting its use to people 65 and older and those 12 and up with underlying health conditions... 
    Via Benzinga
    Where BioNTech Stands With Analysts
     
    Via Benzinga
    Eli Lilly, Affirm And Regeneron Are Among Top 12 Large-Cap Losers Last Week (May 5-May 9): Are The Others In Your Portfolio?
    The worst performing large-cap stocks last week: ARGENX, VRTX, SMMT, MMYT, REGN, RKT, BNTX, AFRM, FNF, LLY, AUR, DASH. Any in your portfolio? 
    Via Benzinga
    Market Monitor May 7 ( Hims & Hers Health, Upwork UP - Palantir, Monderna DOWN)
    Markets slide on vaccine regulation fears, trade uncertainty, and cautious earnings despite strong tech and consumer stock moves. 
    Via Chartmill
    Why BioNTech Stock Got Trounced on Tuesday
    Via The Motley Fool
    BioNTech Appoints Novartis Executive As Finance Chief, Reaffirms 2025 Outlook Focusing on Oncology Expansion
    BioNTech's Q1 revenue hit $192 million, beating estimates; company confirms 2025 outlook and names new CFO ahead of oncology-focused expansion. 
    Via Benzinga
    BioNTech Announces First Quarter 2025 Financial Results and Corporate Update
    From BioNTech SE
    Via GlobeNewswire
    BioNTech Announces Appointment of Ramón Zapata to Management Board as Chief Financial Officer
    From BioNTech SE
    Via GlobeNewswire
    Want Safe Dividend Income in 2025 and Beyond? Invest in the Following 3 Ultra-High-Yield Stocks.
    There's no need to track down complicated and obscure businesses. Some of the market's best income-producing stocks are hiding in plain sight. 
    Via The Motley Fool
    Topics Bonds World Trade
    Trump-Era FDA Appointees Request New Trials For Novavax COVID Vaccine, Reportedly Delaying Approval Timeline
    The President Donald Trump administration's request for Novavax Inc. to conduct new clinical trials for its COVID-19 vaccine has created uncertainty across the vaccine industry, potentially affecting... 
    Via Benzinga
    Topics Government
    Why Is Summit Therapeutics Stock Trading Higher On Monday?
    Summit Therapeutics highlights China approval of Akeso's ivonescimab for NSCLC, with enrollment ongoing for Phase 3 HARMONi-7 trial. 
    Via Benzinga
    Why Biotech Stars Summit Therapeutics and BioNTech Plunged, Even as This Chinese Rival Surged Today
    Via The Motley Fool
    BioNTech to Present Clinical and Preclinical Data Across mRNA and Next-Generation Immuno-Oncology Priority Programs at AACR 2025
    From BioNTech SE
    Via GlobeNewswire
    Novavax's COVID-19 Vaccine Nears FDA Full Approval, Stock Jumps
    Novavax's COVID-19 vaccine showed fewer side effects than Pfizer's in a Utah study as FDA seeks more data before full approval decision. 
    Via Benzinga
    BioNTech Surges On Summit's Coattails. But Can They Take On Merck?
    BioNTech is on the rise after Summit Therapeutics unveiled promising results for its PD-1- and VEGF-blocking drug. 
    Via Investor's Business Daily
    Amphenol Posts Better-Than-Expected Results, Joins SAP, Tesla, Pegasystems And Other Big Stocks Moving Higher On Wednesday
     
    Via Benzinga
    BioNTech to Report First Quarter 2025 Financial Results and Corporate Update on May 5, 2025
    From BioNTech SE
    Via GlobeNewswire
    10 Health Care Stocks Whale Activity In Today's Session
     
    Via Benzinga
    Novavax Covid Vaccine Shows Milder Side Effects Than Pfizer-BioNTech's Shot: Study
    Novavax updated Covid vaccine showed fewer and milder side effects than Pfizer-BioNTech's in a Utah study. 
    Via Benzinga
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    70 71 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.